Search
HPA-23
go.drugbank.com/drugs/DB17739ExperimentalHPA-23 is an investigational antiviral compound.[A259142]
Acetoxolone
go.drugbank.com/drugs/DB13640ExperimentalCategories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)R112
go.drugbank.com/drugs/DB06252ExperimentalR112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.
Erythroxylum catuaba bark
go.drugbank.com/drugs/DB14300Investigational"Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _Erythroxylum_ genus, though this name is also applied to infusions of plants belonging to other genera … [A215262] The infusion is thought to carry stimulant and aphrodisiac effects,[A215262] and catuaba made specifically with _Trichilia catigua_ has been investigated for use in depression.[A215267]
Biomed 101
go.drugbank.com/drugs/DB05851InvestigationalBiomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid. … Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.
Deudextromethorphan
go.drugbank.com/drugs/DB19054InvestigationalDeudextromethorphan is under investigation in clinical trial NCT02153502 (Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an
Mofegiline
go.drugbank.com/drugs/DB19621ExperimentalThe usage of the INN stem '-giline' in the name indicates that Mofegiline is a monoamine oxydase (MAO)-inhibitor type B. Mofegiline has a monoisotopic molecular weight of 197.1 Da.
Saredutant
go.drugbank.com/drugs/DB06660InvestigationalSaredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Trastuzumab botidotin
go.drugbank.com/drugs/DB17413ExperimentalA166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable